Incorporating Real-World Evidence into Clinical Decisions in NSCLC - Episode 8
Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC
Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In the video series, Bazhenova and Albrecht discussed the following:
- Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC
- EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data
- Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies
- EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions
- Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC
- Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC
- Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC
To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
